Edgestream Partners’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-34,798
Closed -$513K – 1013
2024
Q3
$513K Sell
34,798
-94,791
-73% -$1.48M 0.02% 697
2024
Q2
$1.8M Buy
129,589
+9,133
+8% +$129K 0.09% 369
2024
Q1
$1.89M Buy
+120,456
New +$1.86M 0.09% 345
2023
Q4
– Sell
-96,062
Closed -$1.18M – 983
2023
Q3
$1.18M Buy
96,062
+33,379
+53% +$496K 0.09% 345
2023
Q2
$1.01M Buy
62,683
+27,093
+76% +$446K 0.09% 356
2023
Q1
$620K Sell
35,590
-17,005
-32% -$242K 0.07% 369
2022
Q4
$486K Sell
52,595
-154,832
-75% -$1.44M 0.05% 373
2022
Q3
$1.79M Buy
+207,427
New +$2.06M 0.14% 209

Other funds holding NEO

Edgestream Partners's NEO Position: Q4 2024 in Review

Edgestream Partners sold out of NeoGenomics (NEO) in Q4 2024, closing a stake of 34,798 shares — an estimated $513K sold.

Edgestream Partners first reported a position in NEO in Q3 2022 and held it in 8 quarters. The position peaked at $1.89M in Q1 2024. 253 funds tracked by Wall St. Rank hold NEO as of Q4 2024.

  • Edgestream Partners reported no remaining NeoGenomics position as of Q4 2024 after selling out during the quarter.
  • Edgestream Partners sold 34,798 NeoGenomics shares in Q4 2024, an estimated $513K.
  • Edgestream Partners first reported a position in NeoGenomics in Q3 2022 and held it in 8 quarters.
  • Edgestream Partners's NeoGenomics position peaked at $1.89M in Q1 2024.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2024.

Based on Edgestream Partners's 13F filing for Q4 2024, filed 7 Feb 2025.